Alcidion Expands Patient Flow Platform With Telstra Health Kyra Acquisition

Nelson Advisors
May 20
3 min read

The Transaction

Alcidion Group (ASX: ALC) signed an Asset Sale Agreement on 16th May 2026 to acquire three Kyra patient flow products from Telstra Health: Kyra Patient Flow Manager, Kyra Queue Manager, and Kyra IQ. The upfront cash consideration is $3.0 Million, funded from Alcidion's existing cash reserves of $15.1 Million (no debt as of 31st March 2026), with a further earn-out of up to $1.0 Million tied to recurring revenue thresholds over 12 months post-completion. Completion is expected by end of June 2026.

What Kyra Does

The Kyra suite is a proprietary set of digital solutions addressing patient flow and data access across hospital inpatient and outpatient settings:

Kyra Patient Flow Manager – real-time oversight of a patient's hospital journey from admission to discharge
Kyra Queue Manager – outpatient queuing and appointment flow management
Kyra IQ – business intelligence and operational analytics, enabling near real-time performance insights to support proactive decision-making

The platform integrates data from Patient Administration Systems, pathology, radiology, EMRs, and diet systems into a unified bed management and journey board interface.

Deal Economics

Metric	Value
Upfront consideration	$3.0M AUD
Earn-out potential	Up to $1.0M AUD
FY26 forecast revenue	$3.7M AUD
Recurring revenue share	>90%
FY26 forecast EBITDA	~$1.1M AUD
Implied EBITDA multiple	2.7x

The deal is projected to be earnings accretive from completion, given the 2.7x EBITDA multiple and the high proportion of sticky, recurring product revenue.

Strategic Rationale for Alcidion

This is a classic tuck-in acquisition that delivers several compounding benefits:

Geographic expansion: Extends Alcidion's footprint into Queensland (where Kyra products dominate among Hospital & Health Services), plus new sites in Victoria, Western Australia, and Tasmania — both public and private sector
Net-new customer base: Of the ~33 acquired customers, only two are existing Alcidion clients, immediately expanding its installed base
Customer tenure: The top 10 customers average a ~10-year relationship, indicating deep clinical workflow integration and low churn risk
Cloud migration runway: CEO Kate Quirke flagged the opportunity to transition Kyra customers from legacy on-premise systems onto Alcidion's modern cloud-enabled Miya Precision platform
UK relevance: The deal also strengthens Alcidion's position in the UK, where its Miya Flow product is already deployed under the NHS G-Cloud framework at £385,000 per unit per year

Competitive Context

Alcidion is positioning itself as the leading enterprise patient flow provider across Australia, New Zealand, and the UK. Its Miya Precision platform (comprising Miya Flow, Miya Access, and Miya Command) already serves major health systems including Alfred Health in Melbourne and NHS Trusts in England and Scotland.

The Kyra acquisition consolidates what had been a competitive product set under a single ownership structure, reducing fragmentation in the ANZ market and removing a Telstra Health-branded alternative from the landscape.

M&A Angle

From an investment banking perspective, the deal structure is notable for its discipline: a 2.7x EBITDA entry multiple with >90% recurring revenues is highly attractive for a SaaS-adjacent healthcare IT asset, and the earn-out mechanism aligns vendor incentives with post-close performance.

Telstra Health's decision to divest Kyra, while retaining its broader health IT portfolio, reflects a broader rationalisation trend among telco-owned health subsidiaries that have struggled to compete with pure-play digital health specialists. For Alcidion, this fits a consolidator strategy in a fragmented ANZ HealthTech market, complementing its earlier Novari Health partnership for waitlist and referral management.

Nelson Advisors > European MedTech and HealthTech Investment Banking

Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital

Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb

Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk

#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech